| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 32,000 | $36.49 | $1,167,680.00 | -44.4% | |
| Jul 5, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Buy | 266,667 | $15.00 | $4,000,005.00 | +11.7% | |
| Jul 5, 2017 | AKBA Akebia Therapeutics, Inc. | Satter Muneer A58 | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | +51.7% | |
| Jul 5, 2017 | ANIK Anika Therapeutics, Inc. | Sherwood Charles H | President, CEO, Director | Sell | 14,201 | $50.03 | $710,544.16 | -2.8% | |
| Jul 3, 2017 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 990 | $14.27 | $14,127.30 | -4.0% | |
| Jul 3, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $58.11 | $87,165.00 | -15.8% | |
| Jul 3, 2017 | AKBA Akebia Therapeutics, Inc. | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,399 | $14.26 | $19,946.52 | -1.3% | |
| Jul 3, 2017 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,554 | $14.26 | $22,156.47 | -1.4% | |
| Jul 3, 2017 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 307,911 | $4.00 | $1,230,932.80 | -62.9% | |
| Jun 30, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $37.42 | $1,796,286.00 | -16.7% | |
| Jun 30, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $37.42 | $1,796,286.00 | -16.7% | |
| Jun 30, 2017 | MRMD Marimed Inc. | Levine Jon R | CFO, Treasurer And Secretary | Buy | 19,495,000 | $0.00 | - | +285.6% | |
| Jun 23, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 2,556 | $44.90 | $114,774.37 | -9.3% | |
| Jun 23, 2017 | AVDL Avadel Pharmaceuticals Plc | Broadfin Healthcare Master Fund Ltd | 10% Owner | Sell | 261,000 | $10.68 | $2,786,600.00 | -3.0% | |
| Jun 23, 2017 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 48,000 | $37.15 | $1,783,360.00 | -20.0% | |
| Jun 23, 2017 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 48,000 | $37.15 | $1,783,360.00 | -20.0% | |
| Jun 22, 2017 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Legal Officer | Sell | 35,000 | $19.75 | $691,250.00 | -100% | |
| Jun 22, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $84.43 | $17,730,720.00 | -0.2% | |
| Jun 21, 2017 | SCYX Scynexis Inc | Hastings David C | Director | Buy | 20,000 | $1.75 | $35,000.00 | New | |
| Jun 20, 2017 | LNTH Lantheus Holdings, Inc. | Avista Capital Partners Gp, LLC | 10% Owner | Sell | 3,000,000 | $14.87 | $44,610,000.00 | -32.3% | |
| Jun 20, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director, 10% Owner | Sell | 3,000,000 | $14.87 | $44,610,000.00 | -32.3% | |
| Jun 20, 2017 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 215,000 | $83.05 | $17,855,363.00 | -0.2% | |
| Jun 19, 2017 | TLPH Talphera, Inc. | Perceptive Advisors LLC51 | 10% Owner | Sell | 875,000 | $2.40 | $2,100,000.00 | -16.2% | |
| Jun 19, 2017 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 56,420 | $21.29 | $1,201,106.00 | -1.2% | |
| Jun 15, 2017 | AVDL Avadel Pharmaceuticals Plc | Cerutti Guillaume | Director | Sell | 26,560 | $10.46 | $277,817.60 | -53.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.